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Abstract
Background: The tumor suppressor KLF6 and its oncogenic cytoplasmic splice variant KLF6-SV1 represent a paradigm in
cancer biology in that their antagonistic cancer functions are encoded within the same gene. As a consequence of splicing,
KLF6-SV1 loses both the C-terminus C2H2 three zinc finger (ZF) domain, which characterizes all KLF proteins, as well as the
adjacent 59 basic region (5BR), a putative nuclear localization signal (NLS). It has been hypothesized that this NLS is a
functional domain critical to direct the distinct subcellular localization of the tumor suppressor and its splice variant.
Methodology/Principal Findings: In this study, we demonstrate using EGFP fusion constructs that KLF6/KLF6-SV1 nucleo-
cytoplasmic transport is not regulated by the 59 basic region but activated by a novel NLS encoded within the ZF domain,
and a nuclear export signal (NES) located in the first 16 amino acids of the shared N-terminus sequence. We demonstrate
KLF6 nuclear export to be Crm1-dependent. The dysregulation of nucleo-cytoplasmic transport when disrupting the KLF6
NLS using site-directed mutagenesis showed that its integrity is necessary for appropriate protein stability. Moreover, these
mutations impaired transcriptional induction of two KLF6 well-characterized target genes, E-cadherin and p21, as shown by
RT-PCR and luciferase promoter assays. The addition of the ZF domain to KLF6-SV1 results in its nuclear localization and a
markedly decreased half-life similar to wild type KLF6.
Conclusions/Significance: We describe the domains that control KLF6 nucleo-cytoplasmic shuttling and how these
domains play a role in KLF6 protein half-life and tumor suppressor function. The results begin to mechanistically explain, at
least in part, the opposing functions of KLF6 and KLF6-SV1 in cancer.
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Introduction
KLF6 is a tumor suppressor gene and member of the Kru ¨ppel-
like factor family of transcriptional regulators involved in
development and differentiation as well as in growth signaling
pathways, apoptosis, proliferation and angiogenesis [1,2]. The
tumor suppressor function of KLF6 has been widely confirmed
through its loss and mutation in a number of cancers and the
ability to reduce colony formation in cultured cells [1,3,4–14].
Like all members of the KLF family, KLF6 is characterized by
three C-terminus C2H2 zinc fingers (ZF) that form the DNA
binding domain and an N-terminus activation domain [15].
Intriguingly, KLF6 is alternatively spliced into KLF6-SV1, a
cytoplasmic protein that lacks the canonical KLF family DNA
binding domain and the contiguous 59 basic region (5BR),
considered a putative NLS, which are both replaced by a novel
C-terminal 21 amino acids (16, Figure 1A). While KLF6-SV1
appears to localize exclusively in the cytoplasm, KLF6 is present in
both the nucleus and cytoplasm [16]. To date, the distinct
subcellular localization differences between KLF6 and KLF6-SV1
have been attributed, respectively, to the presence or absence of
the 59 basic region. KLF6-SV1 was first shown to promote tumor
growth, cancer development and metastasis in prostate cancer
(PCa) [1]. Since its original identification in PCa, increased
expression of this C-terminus truncated splice variant has been
correlated with metastasis and poor survival not only in prostate
cancer [1,16,17] but also in nasopharyngeal carcinoma [14],
colorectal cancer [6], lung cancer [18], hepatocellular carcinoma
[8], gliobastoma [4], ovarian cancer [3], head and neck squamous
cell carcinoma [13] and pancreatic cancer [19]. Given the cancer-
relevant and antagonistic functions of KLF6 and KLF6-SV1 it will
be important to define the functionality of the putative NLS, the
5BR, as well as the role of nucleo-cytoplasmic shuttling in
regulating KLF6/KLF6-SV1 function.
Regarding subcellular localization domains, the putative NLS
has been shown to be functional in KLF1 and KLF4. Moreover,
the KLF zinc finger domain has also been implicated in driving
nuclear localization of these proteins [20–23]. On the other hand,
only KLF5 has been demonstrated to possess a nuclear export
signal (NES) [24]. In general, subcellular trafficking depends on
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12639the presence of specific functional domains within protein
sequences. Nuclear localization signals (NLS), whether classical
(monopartite or bipartite) or not, are motifs that direct proteins
into the nucleus [25–28]. These signals, which are recognized by
protein carriers called importins, are characterized by the presence
of basic residues, Lys and Arg. In many cases these signals are
Figure 1. Diagram of the different EGFP constructs. A, KLF6 and KLF6-SV1 protein sequences. All Leu (L) and Ile (I) residues are highlighted in red.
The 16 amino acids (aa) that form the KLF6 NES are in bold. Other hydrophobic aa within the NES are underlined. The continuous underlines in the C-
terminus of the KLF6 sequence represent the three zinc fingers. The aa which differ between the two proteins are highlighted in blue. B, Diagram of the
EGFP constructs used to interrogate and define the KLF6 NLS. C, Diagram of the N-terminus deletions used to identify and investigate the KLF6 NES.
doi:10.1371/journal.pone.0012639.g001
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protein activity [29]. For example, in many transcription factors,
NLSs are localized in the proximity of their DNA binding domains
[20,30]. On the other hand, nuclear export signals (NES), which
are recognized by exportins and are characterized by hydrophobic
amino acids [31,32], are responsible for the transport of proteins
out of the nucleus, back to the cytoplasm. The most common
protein involved in exporting cargo from the nucleus is the
transporter protein Crm1/Xpo1, first discovered in yeast [33–36].
Subcellular localization and protein turnover are two related
events that are tightly regulated and control the function of
different tumor suppressor proteins. Examples include Rb [37],
PTEN [38], BRCA1, p53 and FOXO [39,40]. Mutations in the
corresponding nuclear import-export domains of these proteins
disrupt transporter binding, which, in turn, alter their nucleo-
cytoplasmic shuttling and, therefore, their normal spatiotemporal
dynamics. Among different consequences, protein mislocalization
results in abnormal protein turnover and altered function that can
promote cell transformation and tumor development [39,41–42].
In this work, we demonstrate that the functional KLF6 NLS is
contained within the zinc finger domain but does not include the
highly conserved contiguous 59 basic region (5BR). Moreover, we
also identify and characterize a functional NES that regulates
KLF6 nucleo-cytoplasmic shuttling in a Crm1-dependent manner.
Together, these domains appear to regulate KLF6 nucleo-
cytoplasmic transport as well as regulate the half-life of both
KLF6 and KLF6-SV1. In sum, these results begin to explain the
differences in subcellular localization, half-life and, possibly,
function between KLF6 and KLF6-SV1 and how KLF6 gene
mutations in these domains and the increase in alternative splicing
may result in tumorigenesis.
Results
The KLF6 C-terminus zinc finger domain defines nuclear
localization
To investigate whether KLF6 possesses a functional NLS, we
generated a series of four constructs encoding truncated KLF6-
derived proteins fused to the reporter protein EGFP. The fusion
proteins consisted of: pEGFP-KLF6, which encodes the full length
KLF6 protein; pEGFP-SV1, full length KLF6-SV1; pEGFP-5BR,
the 59 basic region (5BR); and pEGFP-ZF1ZF2ZF3, the entire
KLF6 zinc finger (ZF) domain (Figure 1B). The constructs were
transfected into Hela cells and 293T cells and after 24 h their
subcellular localization was analyzed by fluorescence microscopy.
In agreement with our previous immunohistochemistry findings
[16], KLF6 was present both in the nucleus and cytoplasm with
areas of intense perinuclear staining, while KLF6-SV1 localized
exclusively in the cytoplasm (Figure 2 and Figure S1). The 59 basic
region alone was unable to drive EGFP into the nucleus and cells
showed an equal nucleo-cytoplasmic distribution, similar to EGFP
control cells. In contrast, cells over-expressing the complete ZF
domain had an exclusive nuclear localization pattern (Figure 2 and
Figure S1).
To dissect the relative importance of each one of the three ZFs
with regard to KLF6 nuclear localization, we engineered three
additional constructs wherein each ZF was independently
expressed and interrogated: pEGFP-ZF1, pEGFP-ZF2 and
pEGFP-ZF3 (Figure 1B). After expressing these constructs in
Hela cells, ZF1 localization was shown to be similar to that of wild
type KLF6 (Figure 2). Namely, ZF1 had predominant cytoplasmic
staining with some nuclear and perinuclear expression. In
contrast, ZF2 and ZF3 resulted in a more equivalent nucleo-
cytoplasmic distribution. Nonetheless, ZF2 expressing cells had a
more easily distinguishable nuclear staining pattern than ZF3 cells
(Figure 2).
It has been previously proposed that the basic residues within
the ZFs of Kru ¨ppel-like factor KLF1 may represent a common
NLS motif for all KLF members [21]. It has also been
demonstrated that mutations in these basic residues only affect
transport but not DNA binding of KLF1 [21]. Given these
previous findings, we therefore mutated the basic residues within
ZF1 and ZF2 to more precisely define and map the amino acids
involved in KLF6 nuclear localization. Using site-directed
mutagenesis we replaced a number of Arg and Lys residues
within the ZF domain with Ala (Figure 3A). In total, 11 residues
were replaced in both zinc finger domains. The loss of the 5 basic
residues in ZF1 drastically decreased the number of cells with
nuclear and perinuclear localization and increased the number of
exclusively cytoplasmically staining cells. Replacement of the 6
basic residues in ZF2, along with the altered ZF1, further increased
the number of cells with cytoplasmic KLF6 localization
(Figure 3B). This suggested that in our experimental system, while
ZF1 may be the main driver of KLF6 nuclear localization, ZF2
plays a minor but important role.
Given these findings, one hypothesis that would explain the
cytoplasmic localization of KLF6-SV1 is that absence of the ZF
domain, and not the 59 basic region, results in its distinct
subcellular localization. To test this, we engineered a KLF6-SV1
construct that possessed all three KLF6 ZFs (KLF6-SV1-Z1Z2Z3).
The addition of the complete ZF domain to the chimeric protein
resulted in complete re-localization of KLF6-SV1 from the
cytoplasm into the nucleus (Figure 3B).
KLF6 has an NES that is Crm1-dependent
The nucleo-cytoplasmic localization of KLF6 together with the
presence of a functional NLS supported the idea that KLF6 could
also harbor a functional nuclear export signal (NES). As a first
approach to identify this NES, and in order to investigate whether
KLF6 nuclear export was mediated by Crm1, we treated Hela
cells expressing EGFP-tagged KLF6, KLF6-SV1 or EGFP with
the Crm1 inhibitor Leptomycin B (LMB) [43,44]. In stark contrast
to non-LMB treated cells that continued to display both nuclear
and cytoplasmic staining of KLF6, LMB treatment resulted in
marked KLF6 nuclear accumulation (Figure 4A). Surprisingly,
LMB treatment of KLF6-SV1 transfected cells also resulted in
nuclear enrichment (Figure 4A). This finding suggests that KLF6-
SV1, like the wild type protein KLF6, can also translocate to and
exist within the nucleus. We did not explore further whether this
was the result of an additional NLS within the primary sequence
or possibly through shuttling (‘‘piggy-backing’’) with another
protein, possibly endogenous KLF6.
For mapping the KLF6 NES domain, we initially used an NES
prediction program (http://www.cbs.dtu.dk/services/NetNES/).
Using this in silico approach only one amino acid with a high score
for a putative NES was identified, Ile15. However, manual
inspection of the sequence revealed a large number of hydropho-
bic residues, a common feature of NESs [32], within the first 132
amino acids of the KLF6 protein sequence (highlighted in red in
Figure 1A). In order to test whether this region contained a
functional NES within this region, we generated three overlapping
N-terminus serial deletions and tested their ability to direct
transport (Figure 1C). Before microscope visualization, we
expressed and analyzed by Western-blot all three truncated
proteins (17KLF6, 57KLF6 and 129KLF6), confirming that they
were stable and expressed in similar amounts (Data not shown). As
displayed in Figure 4B, all three constructs, lacking the first 128 aa,
56 aa and 16 aa, respectively, remained in the nucleus suggesting
KLF6 Localization Domains
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shortest deletion, 16aa, at least one functional NES must exist
within this domain and exist within this region.
We then sequentially mutated each of the 9 hydrophobic
residues within these first 16 aa to Ala using site-directed
mutagenesis (Figure S2). The effect of these mutations on nuclear
localization was easily discernible. Only mutations in Val3, Met6,
Phe10, Leu13 or Ile15 increased KLF6 nuclear sequestration
(Figure S2).
The nuclear export rate of a protein depends on the activity of
its NES, which in turn is determined by the strength and
accessibility to the domain [45]. To gain an approximate
understanding of this, we measured the relative strength of the
KLF6 NES. Using the system first described by Henderson et al.,
2000 we compared the KLF6 NES to that of the human
immunodeficiency virus type I (HIV-I) Rev protein. We used three
different constructs: pRev1.4-EGFP, encoding an NES-deficient
Rev protein; pRev1.4 (NES3)-EGFP, expressing Rev plus its own
NES; and pRev1.4 (KLF6 NES)-EGFP that replaces the Rev NES
with that from KLF6. Hela cells over-expressing the NES-deficient
Rev protein (pRev1.4-EGFP) showed complete nuclear localiza-
tion whereas the Rev NES containing protein (pRev1.4 (NES3)-
EGFP) was exclusively cytoplasmic (Figure 5). However, replace-
ment of the Rev NES with the 16 aa KLF6 NES resulted in partial
cytoplasmic relocalization of Rev. Treatment of all 3 transfected
cell lines with LMB resulted in complete relocalization of EGFP
into the nucleus thus suggesting again the Crm1-dependent nature
of the KLF6 NES.
Nucleo-cytoplasmic transport regulates KLF6 and KLF6-
SV1 protein stability
When analyzing their subcellular localization, we noted that
cells over-expressing KLF6 showed, in general, less fluorescence
compared to those over-expressing KLF6-SV1 or EGFP. More-
over, the different chimeric and mutated KLF6 proteins revealed
that fluorescence intensity varied between constructs but not
between experiments (data not shown). As protein stability has
been linked to protein subcellular localization we investigated
whether the half-life of the NLS and NES mutants was different.
We treated Hela cells over-expressing the different proteins with
cycloheximide (CHX) to inhibit de novo protein synthesis and then
harvested protein extracts at different time points for Western-
blotting. In accord with previous findings [46], wild type KLF6
half-life was ,18 min (Figure 6).
As predicted, changes in the NLS and NES sequences affected
protein stability. The ZF1 mutant (KLF6-Z1A5), doubled KLF6
half-life to ,40 min. Additional mutations in ZF2 (KLF6-
Z1A5Z2A6) further significantly increased the half-life (Figure 6).
Deletion of the NES (17KLF6) also resulted in a markedly
increased half-life compared to the wild type protein. The half-life
of 17KLF6 was longer than 1 h. Point mutations in one of the
mapped critical amino acids (mutant L13AKLF6) were also
sufficient to increase KLF6 half-life, having the same effect on half-
life as deletion of the complete NES (Data not shown).
KLF6-SV1 has a markedly longer half-life compared to KLF6,
.1 h [47]. To determine if KLF6-SV1 stability was also
influenced by nucleo-cytoplasmic transport, we added the KLF6
NLS to KLF6-SV1 with the aim of restoring nuclear localization.
We generated the chimeric protein SV1-Z1Z2Z3. After transfec-
tion in Hela cells, SV1-Z1Z2Z3 restored not only KLF6-SV1
nuclear localization but also resulted in a shorter half-life,
,19 min, similar to the half-life of the wild type protein KLF6
(Figure 6).
Nuclear localization affects KLF6 tumor suppressor
function
We next investigated whether the differing subcellular localiza-
tions of KLF6 and KLF6-SV1 may in part underlie their
antagonistic functions. We chose two well-characterized KLF6
transcriptional targets, the transmembrane protein E-cadherin and
the cyclin-dependent kinase inhibitor p21. The expression of these
two genes has been shown to be increased by wild type KLF6 but
not KLF6-SV1 [1,17,48]. We used Hela cells over-expressing
KLF6, KLF6-SV1 or two NLS mutants (KLF6-Z1A5, KLF6-
Z1A5Z2A6) to measure the levels of expression of E-cadherin, by
RT-PCR, and p21, by both RT-PCR and luciferase promoter
assays. As shown in Figure 7A, cells over-expressing wild type
KLF6 doubled E-cadherin expression compared with control
vector (p,0.005). Over-expression of KLF6-SV1 or either of the
KLF6 NLS mutants had no effect on E-cadherin expression
(Figure 7A). Similarly, cells over-expressing KLF6 increased
endogenous p21 expression ,20% (p,0.05) (Figure 7B), and
about 4-fold increase when a p21 promoter fused to luciferase
gene was used (p,0.005) (Figure S3). No changes were detected in
the levels of p21 in cells over-expressing KLF6-SV1 or the two
KLF6 NLS mutants in neither one of the experiments. Figure 7C
shows the level of expression of the different constructs transfected.
Discussion
In this work we define and characterize a number of novel
regulatory domains and test the mechanisms involved in nucleo-
cytoplasmic transport of KLF6 and KLF6-SV1. In turn, these
domains seem to be necessary for regulating protein turnover and
help to establish functional differences between KLF6 and KLF6-
SV1, which have both been shown to play important roles in
cancer initiation, progression and survival and for predicting
outcome. For example, addition of the KLF6 NLS to KLF6-SV1
results in nuclear localization of this oncogenic protein while
markedly decreasing its half-life. Conversely, removing the native
NLS sequence from KLF6 resulted in its loss of nuclear targeting
but also its inability to activate E-cadherin and p21 transcription.
KLF6 is frequently inactivated in a number of human cancers.
Inactivation can occur through multiple mechanisms including
mutation, loss of heterozygosity (LOH), promoter hypermethyla-
tion and/or an increase in alternative splicing [1,5–7,14,16,46,49].
Examination of the published KLF6 mutations demonstrates that
indeed a number of the cancer-defined mutations occur in the
NLS and NES domains (Figure 8). Three mutations map into the
NLS: S215F has been identified in astrocytoma, glioblastoma and
meningioma [46], R243K in nasopharyngeal carcinoma [14], and
L217S in prostate cancer [1,5]. In the NES domain, two
mutations, D2G and M6V, have also been identified in
astrocytoma, glioblastoma and meningioma [50]. Of note, in this
Figure 2. The KLF6 functional NLS resides within the zinc finger domain. Co-localization of KLF6, KLF6-SV1, 5BR or the ZFs EGFP constructs
together with Cherry-H2A, which was used to show nuclear staining. Localization of the different constructs was observed by fluorescence
microscopy. Graphs with the percentage of cells with the different localization are shown on the right. N, Nuclear localization, C, Cytoplasmic
localization, N=C, Nuclear and cytoplasmic distribution within the same cell is equal, N.C, Nuclear localization is more intense than cytoplasmic
localization, N,C, Nuclear localization is less intense than cytoplasmic localization, and PN, perinuclear localization.
doi:10.1371/journal.pone.0012639.g002
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R243 result in either nuclear localization or cytoplasmic
sequestration of KLF6, respectively (Figure 3B, Figure S2 and
Figure 8). Given that we demonstrated M6A mutant to have
increased nuclear localization, it will be of interest to specifically
functionally interrogate the patient-derived KLF6 and KLF6-SV1
M6V mutants, which would both share the mutation, to better
understand if their association with cancer arises from loss of the
tumor suppressor or activation of the oncogenic variant.
Beyond mutational inactivation, dysregulation of KLF6 alter-
native splicing has also been described in a number of cancers and
increased production of KLF6-SV1 is associated with increased
tumor stage [3], chemoresistance [51] and poor prognosis [52]. In
one sense, KLF6-SV1 represents a naturally occurring inactivating
Figure 3. Mutations within the ZFs affect KLF6 nuclear transport. A, Cartoon showing the Ala replacement mutations introduced in ZF1 and
ZF2 and the structure of the chimera SV1-Z1Z2Z3. B, Subcellular localization of the constructs following transfection in Hela cells. Cherry-H2A construct
was used to show nuclear staining. Localization of the different constructs was observed by fluorescence microscopy. Graphs with the percentage of
cells with the different localization are shown on the right. N, Nuclear localization, C, Cytoplasmic localization, N=C, Nuclear and cytoplasmic
distribution within the same cell is equal, N.C, Nuclear localization is more intense than cytoplasmic localization, N,C, Nuclear localization is less
intense than cytoplasmic localization, and PN, perinuclear localization.
doi:10.1371/journal.pone.0012639.g003
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these two proteins can in part be related to their distinct
subcellular localizations.
Our demonstration that the KLF6 zinc fingers also encode the
functional NLS provides further support for the hypothesis by
Pandya et al. [21] that a common NLS is present in the zinc finger
domain of all KLF family members. Distinctions between the
domains do however exist. Different from KLF1 and KLF4 where
all three ZFs appear to be necessary for nuclear localization as well
as the 59 basic region adjacent to them [20–22], ZF1 plays the
main role in defining KLF6 subcellular localization (Figure 2).
Similar results demonstrating a functional role for ZF1 have
also been recently demonstrated for KLF8 [23]. On the other
hand, ZF2,Z F 3 and the KLF6 59 basic region sequence
(PDGRRRVHR) are not sufficient to direct nuclear localization
(Figure 2). These results in deconstructing the functional roles of
each zinc finger are in accord with and help to explain previously
published findings on the subcellular localization of other KLF6
Figure 5. KLF6 presents a CRM1-dependent NES that is of relatively weak strengh. EGFP localization in Hela cells co-transfected with
Cherry-H2A and wild type Rev protein (pRev1.4-EGFP), a NLS mutant Rev protein (pRev1.4-(NES3)-EGFP) or a Rev carrying KLF6 NES (pRev-(KLF6NES)-
EGFP). Cells were treated or not with LMB for 2 h. Both EGFP and the corresponding fields for Cherry-H2A are shown. Graphs with the percentage of
cells with the different localization are shown on the right. N, Nuclear localization, C, Cytoplasmic localization, N=C, Nuclear and cytoplasmic
distribution within the same cell is equal, N.C, Nuclear localization is more intense than cytoplasmic localization, N,C, Nuclear localization is less
intense than cytoplasmic localization, and PN, perinuclear localization.
doi:10.1371/journal.pone.0012639.g005
Figure 4. Identification of a Crm1-dependent KLF6/KLF6-SV1 nuclear export signal. A, Hela cells transfected with EGFP-KLF6, EGFP-KLF6-
SV1 or empty vector were treated with or without LMB for 2 h. B, The subcellular localization of truncated KLF6 constructs is shown. Cherry-H2A
construct was used to show nuclear staining. Localization of the different constructs was observed by fluorescence microscopy. Graphs with the
percentage of cells with the different localization are shown on the right. N, Nuclear localization, C, Cytoplasmic localization, N=C, Nuclear and
cytoplasmic distribution within the same cell is equal, N.C, Nuclear localization is more intense than cytoplasmic localization, N,C, Nuclear
localization is less intense than cytoplasmic localization, and PN, perinuclear localization.
doi:10.1371/journal.pone.0012639.g004
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possesses ZF2 and ZF3, localizes in the cytoplasm [16]. Splice
variant 3 (KLF6-SV3), which maintains ZF1 but not ZF2 and ZF3
localizes to the nucleus (Martignetti and Camacho-Vanegas,
unpublished results).
Recently, Du et al. [24] described the presence of an NES in a
KLF family member. The KLF5 NES was shown to be Crm1-
dependent and present between aa 119–139 within the regulatory
domain and located near a SUMO motif that regulates nuclear
export. In this work, we describe that the first 16 amino acids of
the common KLF6 and KLF6-SV1 protein sequence contain a
NES that might be Crm1-dependent because KLF6 is entrapped
in the nucleus following treatment with LMB. Targeted deletions
and mutations in some of the hydrophobic residues within this 16
aa domain also resulted in increase in nuclear accumulation. In
comparing the strength of the NES to the well-characterized Rev
protein, the KLF6 NES was shown to be weaker and thus similar
to that of other transcription factors such as p53 and p53-regulated
genes like p21 and Hmd2 [45].
One unexpected finding from these studies was the observation
that KLF6-SV1, which lacks the KLF6 NLS and which we have
previously shown to be localized primarily in the cytoplasm [16]
was nonetheless found to be partially relocalized to the nucleus
when cells were treated with LMB, a Crm1 inhibitor. This
suggests that KLF6-SV1 can be transported into the nucleus in
an NLS-independent manner, possibly through binding KLF6 or
other actively nucleo-cytoplasmic shuttled proteins (piggy-backing).
This has been shown to occur with other tumor suppressors
including BRCA1, whose NLS-lacking alternatively splice
isoforms are transported into the nucleus following DNA damage
[53]. In this instance, nuclear transport is mediated through
binding to BARD1, another tumor suppressor that heterodi-
Figure 6. Effects of KLF6 nucleo-cytoplasmic localization domains on protein half-life. Western-blots showing half-life experiments for the
wild type and different NLS and NES mutants. Cells were harvested at the times indicated after CHX treatment. Membranes were probed with anti-
GFP to detect KLF6, KLF6-SV1 and the mutants, and with anti-actin as a loading control. The graph represents the values obtained after densitometry
analysis. The percentage of remaining protein after CHX addition is plotted.
doi:10.1371/journal.pone.0012639.g006
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damage repair [53].
Our results link, for the first time, nucleo-cytoplasmic transport
of a KLF family member to protein stability. Given KLF6’s tumor
suppressor function and KLF6-SV1’s oncogenic/anti-apoptotic
function, this finding may have broad implications. Previous
studies showed that KLF6 is ubiquitinated and degraded via the
proteasome and has a short half-life of ,15 min [47]. KLF6-SV1
half-life is appreciably longer [54]. The mechanisms underlying
their turnover remained unknown. Here we demonstrate that
regulated turnover requires an intact NLS and NES. Disruption of
either of them modified KLF6 protein stability. Furthermore,
Figure 7. KLF6 intact NLS is necessary for KLF6 tumor suppressor function. RT-PCR data showing endogenous levels of E-cadherin (panel
A), p21 (panel B) and the different constructs (panel C). Expression levels were calculated by normalizing each cDNA to GAPDH and then using this
normalized value to calculate fold change to the EGFP empty vector value. All experiments were performed at least three times and in triplicate.
Statistical significance was determined by two tailed, two-sample equal variance T-test (‘=p,0.05 and ‘‘=p,0.005 to EGFP; *= p,0.05 and **=
p,0.005 to EGFP-KLF6).
doi:10.1371/journal.pone.0012639.g007
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localization but also decreased protein stability, resulting in a
protein with a half-life more similar to wild-type KLF6.
In further agreement with our hypothesis that regulation of
nucleo-cytoplasmic transport is a critical determinant of KLF6
function, we demonstrated that mutations in the KLF6 NLS
domain result in decreased transcriptional activation of two
cancer-relevant targets, p21 and E-cadherin. Access to the nuclear
compartment might be a first step of regulation prior to activating
target promoters. This has also been demonstrated recently for
another KLF member, KLF8, in which the presence of an intact
NLS is needed for increased Cyclin D1 transcriptional activation
and increased cell proliferation [23]. Ultimately, and given the
demonstrated role of KLF6 and KLF6-SV1 in human cancers, it
will be important to examine the possible post-traslational
modifications which may provide additional layers of regulation
to their nucleo-cytoplasmic regulation as well as the mechanism(s)
which allow NES-independent KLF6-SV1 nuclear import. The
regulation and cellular consequences of nuclear KLF6-SV1
remain to be determined.
Materials and Methods
Generation of plasmids and site-directed mutagenesis
constructs
The pEGFP-KLF6 plasmid was generated by amplifying the
complete KLF6 coding sequence from the pCIneo-KLF6
construct [1] using the primers fwd-KLF6pCIneo and rev-
KLF6pCIneo (Table S1). The resulting amplicon was then
subcloned using EcoRI sites into the pEGFP-C3 vector (Clontech).
The pEGFP-KLF6-SV1 plasmid was generated by cloning the
entire KLF6-SV1 coding sequence obtained by EcoRI enzymatic
restriction digest from the pCIneo-KLF6-SV1 vector [48] into
pEGFP-C3. The pEGFP-5BR construct contains the KLF6
putative NLS sequence (PDGRRRVHR) that was cloned
EcoRI/BamHI in pEGFP-C3 from annealing of complementary
forward and reverse primers (Table S1). The pEGFP-ZF1ZF2ZF3
construct was made using the primers fwd-Z1Z2Z3 and rev-Z1Z2Z3
(Table S1) to amplify KLF6 zinc fingers (ZF) from the pCIneo-
KLF6 vector and then cloned BamHI into the pEGFP-C3 vector.
Plasmids pEGFP-ZF1, pEGFP-ZF2 and pEGFP-ZF3, carrying
individual KLF6 ZFs, were obtained by cloning KLF6 ZF1
(BamHI), ZF2 (EcoRI/BamHI), and ZF3 (EcoRI/BamHI) se-
quences amplified by PCR from the pCIneo-KLF6 construct and
using the primers fwd-Z1Z2Z3/rev-Z1, fwd-Z2/rev-Z2 and fwd-
Z3/rev-Z1Z2Z3 (Table S1), respectively. The pEGFP-SV1-Z1Z2Z3
construct was obtained by cloning KLF6-SV1 coding sequence
into the pEGFP-ZF1ZF2ZF3 plasmid digested with EcoRI.
We generated the N-terminus deletion constructs lacking the
first 128 (pEGFP-129KLF6), 56 (pEGFP-57KLF6) and 16
(pEGFP-17KLF6) amino acids (aa), using the primer combinations
fwd-129-283/rev-KLF6pCIneo, fwd-57-283/rev-KLF6pCIneo
and fwd-17KLF6/rev-KLF6pCIneo, respectively (Table S1).
EcoRI digested amplicons were then subcloned into the pEGFP-
C3 vector.
Point mutations in the NES and NLS were sequentially
generated in the pEGFP-KLF6 plasmid using commercially
available kits following the manufacturer’s recommendations
(Stratagene, USB Corporation) and the primers listed in Table S2.
The construct pRev-(KLF6NES)-EGFP was made by cloning
annealed primers containing the KLF6 NES sequence in the
plasmid pRev1.4(NES3)-EGFP digested with BamHI/AgeI.
Plasmids pRev1.4 (NES3)-EGFP and pRev1.4-EGFP were kindly
donated by Dr. Eric Henderson (Westmead Institute for Cancer
Research, Sydney, Australia).
All primer sequences are shown in Table S1 and S2. All
expression constructs were confirmed by DNA sequencing in both
orientations prior to their use.
Growth and maintenance of cell lines
All cell lines were purchased from the American Type Culture
Collection (Manassas, VA). Cells were grown and maintained in
DMEM media (CellgroH) supplemented with 10% FBS (Gibco)
and 1% Penicillin/Streptomycin (CellgroH). Cells were transfected
with Lipofectamine
TM 2000 reagent according to the manufac-
turer’s recommendations (Invitrogen).
Western blot and half-life analysis
Protein extracts for Western blotting were obtained by lysing the
cells with radioimmunoprecipitation assay buffer following stan-
dard protocols. Protein concentration was measured using the Bio-
Rad DC Protein quantification assay and amounts adjusted such
that equivalent amounts were loaded (7.5 ug). Electrophoresed
proteins were resolved by SDS-PAGE and transferred to a
nitrocellulose membrane. Blots were blocked with 5% non-fat milk
(Labscientific, Inc.) in TBS-Tween buffer. We used the following
primary antibodies: Actin (I-19) (Santa Cruz Biotechnology) and
GFP Living Colors (JL-8) (Clontech). Both primary and secondary
Figure 8. Site-directed and patient-derived mutations in the NES and NLS and their consequences. Site-directed mutations are
highlighted in bold, whereas patient-derived mutations, described in the text, are italicized. Overlapping mutations are shown in both bold and
italics. For previously published data check reference (55).
doi:10.1371/journal.pone.0012639.g008
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milk in TBS-Tween.
For the half-life experiments, Hela cells were transfected with
different constructs. The next day, transfected cells were treated
with 1 mg/ml of Cycloheximide (Sigma). Protein extracts were
obtained at the noted times and then analyzed by Western-blot.
Fluorescent microscopy
EGFP subcellular localization was observed using a fluorescent
microscope (NIKON Eclipse TE 200) with a 206 objective.
Photomicrographs were acquired using Spot Advanced Software
and the Image J program.
For all localization experiments, two wells of a 6-well plate were
transfected and analyzed for each EGFP construct. At the
minimum, six [6] fields were randomly chosen and green cells
were counted in order to calculate the percentages of nuclear (N),
cytoplasmic (C) and perinuclear (PN) cells. In addition, each
experiment was repeated at least three times.
RNA extraction and quantitative real time-PCR (qRT-PCR)
analysis
RNA extraction and qRT-PCR analysis were done as
previously described [51]. Briefly, RNA was obtained from cells
using the Rneasy Mini kit (Qiagen) and treated with DNase
(Qiagen). One ug of RNA was used in each reaction to obtain the
first-strand complementary DNA by reverse transcription using
random primers (Promega). An ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems) was used for the qRT-
PCR. The primer sequences used have been previously described
[3,16,48]. All values were normalized to GAPDH levels. All
experiments were performed in triplicate and validated thrice
independently. Statistical significance was determined by two
tailed, two-sample equal variance T-test (‘=p ,0.05 and
‘‘=p,0.005 to EGFP; *= p,0.05 and **= p,0.005 to
EGFP-KLF6).
Luciferase transactivation assays
Hela cells transfected with a p21 promoter construct (1 ug) and
either KLF6, KLF6-SV1, the NLS mutants or EGFP empty vector
(1 ug) were harvested 24 h after transfection. Dual-LuciferaseH
Reporter Assay kit (Promega, Madison, WI, USA) was used to
extract protein and develop the assay following the manufacturer’s
recommendations. The TK promoter-Renilla Luciferase construct
(Promega, Madison, WI, USA), 10 ng, was used to normalize each
experiment. Luciferase activity was determined for each EGFP
construct by luminescence in a ModulusTM II Microplate
Multimode Reader (Promega, Madison, WI, USA). All experi-
ments were performed in triplicate and validated thrice indepen-
dently. Statistical significance was determined by two tailed, two-
sample equal variance T-test (p,0.005).
Supporting Information
Figure S1 Localization of KLF6, KLF6-SV1, KLF6 NLS and
the ZFs in 293T cells. Co-localization of KLF6, KLF6-SV1, KLF6
NLS or the ZFs EGFP constructs together with Cherry-H2A,
which was used to show nuclear staining. Localization of the
different constructs was observed by fluorescence microscopy.
Found at: doi:10.1371/journal.pone.0012639.s001 (1.17 MB TIF)
Figure S2 Mutations in the N-terminus 16 amino acids results in
increased KLF6 nuclear localization. Subcellular localization of
the different NES mutants. Cherry-H2A construct was used to
show nuclear staining. Localization of the different constructs was
observed by fluorescence microscopy. Graphs with the percentage
of cells with the different localization are shown on the right. N,
Nuclear localization, C, Cytoplasmic localization, N=C, Nuclear
and cytoplasmic distribution within the same cell is equal, N.C,
Nuclear localization is more intense than cytoplasmic localization,
N,C, Nuclear localization is less intense than cytoplasmic
localization, and PN, perinuclear localization.
Found at: doi:10.1371/journal.pone.0012639.s002 (1.62 MB TIF)
Figure S3 p21 promoter luciferase assays for KLF6, KLF6-SV1
and the NLS mutants as well as EGFP empty vector in 293T cells.
Expression levels were calculated by normalizing each luciferase
value to Renilla gene expression and representing the Relative
Luciferase Units (RLU). All experiments were performed at least
three times and in triplicate. Statistical significance was deter-
mined by two tailed, two-sample equal variance T-test (p,0.005).
Found at: doi:10.1371/journal.pone.0012639.s003 (0.08 MB TIF)
Table S1 Primers used for site-directed mutagenesis. ‘P’
represents the primers that are 59 phosphorylated.
Found at: doi:10.1371/journal.pone.0012639.s004 (0.04 MB
DOC)
Table S2 Primers used to generate expression constructs.
Restriction sites are underlined.
Found at: doi:10.1371/journal.pone.0012639.s005 (0.04 MB
DOC)
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